China Resources Boya Bio-pharmaceutical Group Co.,Ltd
博雅生物
300294
Shenzhen Stock Exchange
Company Profile
The company has always focused on the development strategy of "becoming a world-class blood products" and insists on focusing on blood products. The company has the following core competencies: (1) Shareholder Resource Endowment and Management Empowerment The actual controller the company, China Resources Group, is an approved state-owned capital investment company by the State-owned Assets Supervision and Administration Commission of the State Council, with a business covering six major fields: major consumption, comprehensive energy, urban construction and operation, major health, industrial finance, technology and emerging industries. In 2024, China Resources's total assets reached 2.71 trillion yuan, achieving operating income of 932.66 billion yuan and a total profit of 9264 billion yuan. China Resources Group ranked 67th on the 2025 Fortune Global 500. The company's controlling shareholder, China Pharmaceutical, is a leading large pharmaceutical group company in China, ranking among the top three in the industry. Since China Resources Pharmaceutical took control of the company, it has given the company support and empowerment in all aspects, such as strategic management, organizational optimization, talent introduction, risk management and the docking of government resources, laying a solid foundation for the companys long-term and stable development. (2) Clear Strategic Planning The company will always adhere to the strategic goal of "becoming a world-class blood products enterprise and focus on the main business of blood products, and continue to promote the healthy and rapid development of the blood products business. (3) Excellent Plasma Station Expansion andasma Collection Capability The company is one of the few blood products enterprises in the country that has a full range of three products and the qualification to expand plasma stations. It is one of the very few blood products enterprises that have the resource endowment of central enterprises. After China Resources Group became the actual controller of the company, it has given strong support in plasma station application, resource docking, plasma station operation and other aspects. In terms of existing plasma stations, by taking measures such as standardization of business system, standardization of and management, standardization of propaganda and development system, the company has improved the level of plasma station operation and management. At the same time, it has innovated the business model, actively built a local blood donation ecosystem, and improved the plasma collection capability; for new plasma stations, the company has adopted a flexible strategy of renting before building, and has optimized the standardized process of plasma station construction, effectively shortening the construction cycle, thereby accelerating the process of raw material collection. (4) Strong R&D Capability company has a strong technical force, undertaking more than 20 government special projects such as the "863 Program" project of the National and Jiangxi Province Major RD Special Projects, owning more than 200 various patents, and has won the Provincial and Municipal Science and Technology Awards and Excellent New Product Awards for many times. recent years, the company has continuously increased its R&D investment, and has successively launched PCC, factor VIII, highly concentrated intravenous immunoglobulin and other. The research projects such as tetanus immunoglobulin, C1 esterase, vWF factor, subcutaneous injection of human immunoglobulin, andalbumin are progressing smoothly. Among them, tetanus immunoglobulin has completed the listing application and is in the professional evaluation stage, forming a good product team in the and development, which will continue to optimize the company's product structure. In the future, the company will focus on the fields of small nucleic acids and gene therapy and deploy advance, further broadening the product structure and enhancing the company's core (5) Good production capacity The Company has a high level of quality management and is one of the first companies in China to the certification of the new version of GMP for Pharmaceutical Products. The Company adopts process automation control system to control the production process, and has realized the automatic recording of the whole processIP, SIP and key parameters. In accordance with the relevant laws and regulations and technical guidelines requirements, combined with the company's resource conditions, the Company has established a complete management system for pharmaceutical products, which ensures the continuous and stable production of pharmaceutical products that meet the intended use and registration requirements. The Company continues to optimize the production process, and core product collection rate is in the leading position in the industry, especially the fibrinogen prepared by the self-patented method, which is in the forefront of the collection rate market share. (6) Strong marketing capability In recent years, the Company has made significant progress in the construction of marketing team, commercial channel construction and academic promotion system. terms of team building, the Company has established a professional and market-oriented marketing team; in terms of academic promotion, it has basically covered the mainstream hospitals in the country, which strong support for the direct access of products to the terminal market; in terms of commercial channel construction, it has formed a strong combination and complementary advantages with the mainstream commercial. summary, the Company has obvious advantages in terms of the resource endowment and management empowerment of the controlling shareholder, clear strategic planning, excellent plasma station expansion and blood plasma collection capability, R&D capability, good production capacity and strong marketing capability. With the support of the controlling shareholders such as China Resources Group and China Resources Medical, the Company will continue to strive become a world-class blood products company and continuously promote the healthy development of the industry.competitiveness.
Full description
The company has always adhered to the development strategy of "becoming a world-class blood products", insisting on the principle of blood products-oriented, actively stabilizing non-blood products business, and gradually promoting the divestment of non-blood products business. The's business is mainly focused on blood products, supplemented by biochemical drugs, chemical drugs, and raw materials. The specific business is as follows: 1. Blood Products The company is mainly engaged in the research, development, and sales of blood products, including three major categories of products: albumin, immunoglobulin, and coag factors. Albumin is the protein with the highest content in plasma and is also the largest blood product used in China at present. It is widely used in the treatment of tumors, diseases, and diabetes; immunoglobulins refer to the immunoglobulins originally present in the blood and the immunoglobulins produced by specific immunogens, are often used in the treatment of immune diseases, passive immunization of infectious diseases, and treatment, etc.; coagulation factors are the least in the blood. Coag factor products are mainly used for coagulation and hemostasis. The company is one of the important blood products manufacturers in China, and its products cover 10 varieties and31 specifications of products such as human blood albumin, intravenous immunoglobulin (pH4), and coagulation factors. 2. New Biophaceuticals Biochemical Drugs Business New Biopharmaceuticals has been deeply involved in the field of biochemical drug manufacturing, and is one of the first batch of key pharmaceutical in China. It has built a scaled research and development center and production base for biochemical drugs, and established the "Jiangsu Provincial Peptide Drug Engineering Technology Center". After years of development, New Biopharmaceuticals has gradually formed a development pattern of "mainly biochemical drug manufacturing, supplemented by chemical drugs; mainlyable drugs, supplemented by other dosage forms; mainly peptide drugs, supplemented by other types of drugs". New Biopharmaceuticals is involved in multiple drug application fields such as orthopedics, hepatitis, gynecology, and immunomodulation. Its product structure is complete and its specifications are complete. Its core products, such the bone peptide series and the oxytocin series, occupy a leading position in the market. 3. Boya Xinhe Chemical Drugs Business Boya Xin was established in 2014, and its main business is the research, development, and sales of anti-infective, diabetes, and cardiovascular and cerebrovascular. It officially went into operation in 2018, and clarified the integrated development strategy of raw material and formulation with the citalopram project and the statin project the core. However, due to the slow progress of project research and development, the reduction of group procurement, environmental protection policy restrictions and other factors, the products lost their competitive, failed to achieve large-scale production, and the performance did not meet the expectations, Boya Xinhe was in a state of continuous loss. In July 205, CR Bio-Ya and Fuzhou High-tech Zone Finance Investment Group Co., Ltd. officially signed the "Shanghai Property Rights Trading Contract", the company transferred 80% of the equity of Boya Xinhe to it. 4. Anhui Greenke Pharmaceutical Sales Business Anhui Greenke Sales Co., Ltd. was established in 2012. The company has been deeply involved in the field of pharmaceutical sales and has built a wide and efficient sales network a professional service system. After years of hard work, the company has established a certain position in the market with its professional sales team and precise market strategy。